Biotech New Highs: EXACT Sciences Corporation (NASDAQ:EXAS), Synthetic Biologics (NYSEMKT:SYN), Amgen (NASDAQ:AMGN), Prothena Corporation (NASDAQ:PRTA)

A colon cancer screening test under development at Madison-based Exact Sciences Corp. (NASDAQ:EXAS) can detect early-stage cancer better than other noninvasive approaches, according to a study published online Wednesday. EXACT Sciences Corporation (NASDAQ:EXAS) stock performance was 0.21% in last session and finished the day at $14.45. Traded volume was 7.74 million shares in the last session and the average volume of the stock remained 997,245.00 shares. The beta of the stock remained 1.55. EXACT Sciences Corporation (NASDAQ:EXAS) insider ownership is 0.70%.

Synthetic Biologics Inc. (NYSEMKT:SYN) on Mar. 10 announced that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California (UCLA). Synthetic Biologics Inc. (NYSEMKT:SYN) rose 9.52% to $3.45 yesterday on volume of 5.37 million shares. The intra-day range of the stock was $3.25 – $3.64. Synthetic Biologics Inc. (NYSEMKT:SYN) has a market capitalization of 154.06 million.

Amgen (NASDAQ:AMGN) had its target price boosted by Citigroup Inc. to $155.00 in a report issued on Tuesday, Analyst Ratings.Net reports. They currently have a buy rating on the stock. In other Amgen news, Director Carbonnel Francois De unloaded 1,000 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $126.69, for a total value of $126,690.00. Amgen, Inc. (NASDAQ:AMGN)’s stock on March 19, 2014 reported a lower of -0.70% to the closing price of $126.58. Its fifty two weeks range is $90.54 – $127.99. The total market capitalization recorded 95.44 billion. The overall volume in the last trading session was 2.60 million shares. In its share capital, Amgen, Inc. (NASDAQ:AMGN) has 754.00 million outstanding shares.

Prothena Corporation PLC (NASDAQ:PRTA) on Mar. 18 announced that an abstract (Abstract #PB-48) reviewing interim clinical data from its ongoing Phase 1 study of NEOD001 in patients with immunoglobulin light chain (AL) amyloidosis and persistent organ dysfunction will be presented at the XIV International Symposium on Amyloidosis (ISA) in Indianapolis, Indiana. Data in the abstract was current as of January 7, 2014. On Wednesday, shares of Prothena Corporation PLC (NASDAQ:PRTA) advanced 27.53% to close the day at $47.39. Company return on investment (ROI) is -32.70% and its monthly performance is recorded as 65.18%. Prothena Corporation PLC (NASDAQ:PRTA) quarterly revenue growth is 63.19%.